Keywords
nephroprotection
dexrazoxane
carvedilol
doxorubicin
Abstract
Doxorubicin (DOX) is a cytostatic drug with a broad spectrum of anticancer activity that has been used in oncology for over 50 years. Among many adverse effects in humans, the most dangerous is late dilated cardiomyopathy, which appears even years after completion of therapy. However, in cats, the critical organ for the toxic effects of DOX is the kidney. Herein, nephrotoxicity is manifested as azotemia. The main aim of our study was to evaluate the protective effect of dexrazoxane (DEX) and carvedilol (CVD) against the nephrotoxic effects of DOX. Nephrotoxicity studies were performed in a rat model of repeated DOX administration. Analyzed blood morphological, biochemical and histopathological findings revealed that DEX has a dual effect: it positively impacts DOX-induced histological alterations and creatinine levels while negatively affecting urea concentration. Thus, the results do not support univocally recommend DEX to prevent nephrotoxicity caused by DOX in cats. However, further studies using initially lower doses of DEX are needed to assess the prevention of nephrotoxicity in cats clinically treated with DOX.
References
1. Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA,
Oliveira PJ. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev. 2014; 34(1):106-35.
2. Smith TAD, Phyu SM, Akabuogu EU. Effects of administered cardioprotective drugs on treatment response of breast cancer cells. Anticancer Res. 2016;36(1):87-93.
3. Kopecny L, Palm CA, Skorupski KA, Delgado M, Rebhun RB. Risk factors associated with progressive increases in serum creatinine concentrations in cats with cancer receiving doxorubicin. J Vet Intern Med. 2020;34(5):2048-55.
4. Poirier VJ, Thamm DH, Kurzman ID, Jeglum KA, Chun R, Obradovich JE, et al. Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. J Vet Intern Med. 2002;16(6):726-31.
5. Mauldin GN, Matus RE, Patnaik AK, Bond BR, Money SC. Efficacy and toxicity of doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats. J Vet Intern Med. 1988;2(2):60-5.
6. Reiman RA, Mauldin GE, Neal Mauldin G. A comparison of toxicity of two dosing schemes for doxorubicin in the cat. J Feline Med Surg. 2008;10(4):324-31.
7. Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, das Dores Cruz F, Goncalves Brandao SM, Rigaud VOC, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity. J Am Coll Cardiol. 2018;71(20):2281-90.
8. Jirkovský E, Jirkovská A, Bavlovič-Piskáčková H, Skalická V, Pokorná Z, Karabanovich G, et al. Clinically translatable prevention of anthracycline cardiotoxicity by Dexrazoxane is mediated by Topoisomerase II beta and not metal chelation. Circ Heart Fail. 2021;14(11):e008209.
9. Mahoney JA, Bergman PJ, Camps Palau MA, Hull TL. Treatment of doxorubicin extravasation with intravenous dexrazoxane in a cat. Journal of veterinary internal medicine. J Vet Intern Med. 2007;21(4):872-3.
10. Szponar J, Gorska A, Ostrowska-Lesko M, Korga-Plewko A, Tchorz M, Ciechanski E, et al. Assessment of the impact of carvedilol administered together with Dexrazoxan and Doxorubicin on liver structure and function, iron metabolism, and myocardial redox system in rats. Int J Mol Sci. 2024;25(4):2219.
11. Szponar J, Ciechanski E, Ostrowska-Lesko M, Gorska A, Tchorz M, Dabrowska A, et al. The lack of synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the model of chronic anthracycline-induced cardiomyopathy. Int J Mol Sci. 2023;24(12):10202.
12. Ruggiero A, Ferrara P, Attinà G, Rizzo D, Riccardi R. Renal toxicity and chemotherapy in children with cancer. Br J Clin Pharmacol. 2017;83(12):2605-14.
13. Nogueira MM, Lavalle GE, Botelho AFM, Veado JCC, Cassali GD, Paes PR, et al. Doxorubicin nephrotoxicity in cats (Felis catus) with malignant mammary neoplasms. Arq Bras Med Vet Zootec. 2023;75:407-14.
14. Abd-Ellatif RN, Nasef NA, El-Horany HES, Emam MN, Younis RL, El Gheit REA, et al. Adrenomedullin mitigates doxorubicin-induced nephrotoxicity in rats: Role of oxidative stress, inflammation, apoptosis, and pyroptosis. Int J Mol Sci. 2022;23(23):14570.
15. Afsar T, Razak S, Almajwal A, Al-Disi D. Doxorubicin-induced alterations in kidney functioning, oxidative stress, DNA damage, and renal tissue morphology. Improvement by Acacia hydaspica tannin-rich ethyl acetate fraction. Saudi J Biol Sci. 2020;27(9):2251-60.
16. Akindele AJ, Oludadepo GO, Amagon KI, Singh D, Osiagwu DD. Protective effect of carvedilol alone and coadministered with diltiazem and prednisolone on doxorubicin and 5-fluorouracil-induced hepatotoxicity and nephrotoxicity in rats. Pharmacol Res Perspectiv. 2018;6(1):e00381.
17. Hu H, Xie C, Weng Z, Yu P, Wang Y, Shan L. Dexrazoxane alleviated doxorubicin-induced nephropathy in rats. Pharmacology. 2022;107(3-4):206-15.
18. Grant MKO, Seeling DM, Sharkey LC, Choi WSV, Iy Abdelgawad IY, Zordoky BN. Sexual dimorphism of acute doxorubicin-induced nephrotoxicity in C57Bl/6 mice. PloS One. 2019;14(2):0212486.
19. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, et l. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16(25):3267-85.
20. Simůnek T, Stérba M, Popelová O, Adamcová M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009;61(1):154-71.
21. Hori Y, Fujimoto E, Nishikawa Y, Nakamura T. Left ventricular outflow tract pressure gradient changes after carvedilol-disopyramide cotherapy in a cat with hypertrophic obstructive cardiomyopathy. J Vet Cardiol. 2020;29:40-6.
22. Suzuki R, Mochizuki Y, Yuchi Y, Yasumura Y, Saito T, Teshima T, et al. Assessment of myocardial function in obstructive hypertrophic cardiomyopathy cats with and without response to medical treatment by carvedilol. BMC Vet Res. 2019;15(1):376.
23. Delwatta SL, Gunatilake M, Baumans V, Seneviratne MD, Dissanayaka MLB, Batagoda SS, et al. Reference values for selected hematological, biochemical and physiological parameters of Sprague-Dawley rats at the Animal House, Faculty of Medicine, University of Colombo, Sri Lanka. Anim Models Exp Med. 2018;1(4):250-4.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2024 Authors